We discuss some of the program changes coming as part of reform, litigation, and politics.

We discuss the causes and revenue implications in the historic decline in Star Ratings for Medicare Advantage and accompanying prescription drug contracts.

The 2025 Medicare Advantage bid cycle has been one of the most tumultuous yet, as stakeholders took a stab at addressing significant changes to the risk models, the Inflation Reduction Act, significant Star Rating changes, bid resubmissions, unexpected PDP demonstrations, and potential regulatory uncertainty from the Supreme Court.

A recent order for CMS to recalculate Star Ratings could eventually result in a 0.5-point increase for more than 60 Part C contracts under Medicare Advantage plans.

Given the impending changes to the Medicare Advantage Star Ratings, organizations should proactively act to preserve or improve their current ratings.

Healthcare stakeholders must thoroughly evaluate CMS’s 2025 Proposed Rule, including its impacts and integration into the operations of Medicare Advantage plans.

As health plans integrate the latest Medicare Advantage Star Ratings, they should proactively consider how to adjust processes to be best prepared.

With significant changes coming to the Medicare Star Ratings, Medicare Advantage organizations (MAOs) need to adapt to maintain or recover their current tiers.

In this webinar we take a dive into the latest changes by CMS to the Medicare Advantage star ratings programs.

Whether you are new to the Medicare Advantage field or are looking to increase your current Medicare revenue and marketing power, CMS STAR ratings play a critical role in the bid process and the long-term success of your plan.